logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Leukemia Acute Lymphoblastic Leukemia All

    FiltersReset Filters
    5 results

    • asparlas

      (calaspargase pegol)
      Servier Pharmaceuticals LLC
      Usage: ASPARLAS is indicated for use as part of a multi-agent chemotherapy regimen to treat acute lymphoblastic leukemia in pediatric and young adult patients aged 1 month to 21 years.

    • leukine

      (SARGRAMOSTIM)
      Partner Therapeutics, Inc.
      Usage: LEUKINE is indicated for shortening neutrophil recovery and reducing severe infections in adults with acute myeloid leukemia post-chemotherapy, mobilizing progenitor cells for transplantation, accelerating recovery in bone marrow transplants, treating delayed neutrophil recovery, and increasing survival after acute exposure to myelosuppressive radiation in patients up to 17 years.

    • oncaspar

      (Pegaspargase)
      Servier Pharmaceuticals LLC
      Usage: ONCASPAR® is indicated as part of a multi-agent chemotherapy regimen for first-line treatment of acute lymphoblastic leukemia (ALL) in pediatric and adult patients, including those with hypersensitivity to native L-asparaginase.

    • rylaze

      (asparaginase erwinia chrysanthemi (recombinant)-rywn)
      Jazz Pharmaceuticals, Inc.
      Usage: RYLAZE is indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients aged 1 month and older who are hypersensitive to E. coli-derived asparaginase, as part of a multi-agent chemotherapy regimen.

    • xatmep

      (Methotrexate)
      Azurity Pharmaceuticals, Inc.
      Usage: XATMEP is indicated for treating pediatric patients with acute lymphoblastic leukemia (ALL) as part of a chemotherapy regimen and managing active polyarticular juvenile idiopathic arthritis (pJIA) in those who respond inadequately or are intolerant to first-line therapies, including NSAIDs.